ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Drug Firm Ikaria To Split In Two

by Michael McCoy
January 6, 2014 | APPEARED IN VOLUME 92, ISSUE 1

The investor group that owns Ikaria will sell the company’s main business to Madison Dearborn Partners, a private equity firm, in a transaction it values at $1.6 billion. Ikaria markets nitric oxide as a treatment for respiratory failure in infants. The discovery of nitric oxide’s role as a signaling molecule in the cardiovascular system won the 1998 Nobel Prize in Medicine. Ikaria’s owners will retain the firm’s research operation, which will start with $80 million to develop nitric oxide for other applications.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment